Abstract: The present invention regards methods and formulations for the treatment of diabetes and the prevention of autoimmune diabetes. The invention includes the administration of human recombinant GAD65 protein in a pharmaceutically acceptable adjuvant.

Abstract: The present invention relates to methods and formulations for GAD-vaccination to evoke a systemic effect rather that a GAD-specific effect. The present invention may therefore be used in the treatment of disease in humans not bearing on a GAD-specific effect. The invention includes a method to treat an autoimmune disease or disorder by administering at least one sequestered autoantigen in a prime and boost regimen for sensitization purposes followed by a boost for treatment purposes. This may be done upon diagnosis. Examples of sequestered autoantigens include: GAD65, GAD67, Pro-Insulin, Basic Myelin Protein, MOG and Chondrotoin II. The present invention relates to medications and methods for treatment of autoimmune disease within six months from diagnosis.

Abstract: The present invention regards methods and formulations for the treatment of diabetes and the prevention of autoimmune diabetes. The invention includes the administration of human recombinant GAD65 protein in a pharmaceutically acceptable adjuvant.

Abstract: The present invention regards methods and formulations for the treatment of diabetes and the prevention of autoimmune diabetes. The invention includes the administration of human recombinant GAD65 protein in a pharmaceutically acceptable adjuvant.

Abstract: The present invention regards methods and formulations for diagnosis, prevention and treatment of disease. More particularly, the present invention teaches methods and formulations for diagnosis, prevention and treatment with antigen in autoimmune disease, allergy, rejection of transplants and cancer. Examples illustrate how the methods and formulations of the invention may be used for diagnosis and amelioration of autoimmune diabetes in which the 65 kd isotype of glutamic acid decarboxylase (GAD) is a major antigen.

Abstract: The present invention regards methods and formulations for the treatment of diabetes and the prevention of autoimmune diabetes. The invention includes the administration of human recombinant GAD65 protein in a pharmaceutically acceptable adjuvant.

Abstract: The present invention regards methods and formulations for the treatment of diabetes and the prevention of autoimmune diabetes. The invention includes the administration of human recombinant GAD65 protein in a pharmaceutically acceptable adjuvant.

Abstract: The present invention regards methods and formulations for diagnosis, prevention and treatment of disease. More particularly, the present invention teaches methods and formulations for diagnosis, prevention and treatment with antigen in autoimmune disease, allergy, rejection of transplants and cancer. Examples illustrate how the methods and formulations of the invention may be used for diagnosis and amelioration of autoimmune diabetes in which the 65 kd isotype of glutamic acid decarboxylase (GAD) is a major antigen.

Abstract: The present invention regards methods and formulations for diagnosis, prevention and treatment of disease. More particularly, the present invention teaches methods and formulations for diagnosis, prevention and treatment with antigen in autoimmune disease, allergy, rejection of transplants and cancer. Examples illustrate how the methods and formulations of the invention may be used for diagnosis and amelioration of autoimmune diabetes in which the 65kd isotype of glutamic acid decarboxylase (GAD) is a major antigen.

Abstract: A system and a method for evaluation of gastrointestinal function is presented. The system consists of a catheter, a recorder and software. The catheter includes one or more CdTe sensors for measuring isotope activity. The catheter CdTe sensors are placed in the gastrointestinal tract to measure gastric emptying or gastrointestinal output after administration of radiolabeled liquid or solid meals. Data is stored in the recorder or displayed on-line on a computer screen. Other parameters such as pH can be added for a more complete evaluation of gastrointestinal function. The computer software is written for the Windows environment. The software includes provisions for general ambulatory and stationary data acquisition. The software also includes realtime analysis combined with an extensive patient journal where all items are described as objects in understandable userfriendly language connected to a database.

Abstract: A modified GAD especially characterized by a substantially preserved immunogenicity in connection with diabetes compared with a non-modified GAD and a reduced or non-existent effectivity in connection with a GABA-synthesis. The invention relates also to a method for manufacturing a modified GAD, a method for supplying a modified GAD, nucleotide sequence encoding the modified GAD, a vector containing the nucleic acid sequence, a host, a pharmaceutical composition comprising modified GAD and use thereof for treating and/or preventing autoimmune disorders such as IDDM.

Abstract: A method and system for determining the presence of one or more components in a liquid substance including illumination of the substance utilizing a light with at least one definite wave length preferably within the almost infrared area and detecting transmitted and/or reflected light and analyzing the detected light wherein the detection is performed extremely fast so as to detect a step response corresponding to an approaching or fading light pulse transmitted or reflected through the substance.

Abstract: A method and system for the determination of the pH of a fluid by measuring the pH of the fluid and thereafter correcting the pH based upon the determination of measured and/or adjusted values of at least one other parameter, such as PO.sub.2 and PCO.sub.2, which relate to the fluid.

Abstract: An ambulatory system for recording and analyzing gastroesophageal reflux is presented. The system includes a digital recorder, an analysis software package and a catheter for measurement of changes in esophageal impedance. For the first time, gastroesophageal reflux can be detected with a pH above 4 (called alkaline reflux), which is the normal pH environment of the healthy esophagus. In addition, one embodiment of the invention allows for the determination of the direction of flow of the detected material in the esophagus, thus enabling the system to distinguish between swallowed saliva and alkaline gastroesophageal reflux. In yet a further embodiment, the present invention allows for recording and analysis of reflux on a non-invasive basis, by using pairs of externally worn impedance sensors. In another embodiment, the invention measures impedance simultaneously with other bio-parameters, such as pH or pressure.

Abstract: A method for a preferably ambulatory measuring and registration of at least one parameter in relation to the bilirubin presence in a measuring region in the gastrointestinal tract of a patient to determine the bilirubin presence in the region. The method is characterized in that the bilirubin presence determination is made in relation to the pH-value of the fluids in the region. The invention relates also to a system for performing the method.

Abstract: A method of determining the existence and location of an obstruction in a respiratory track includes introducing a first catheter having a first sensing site into the body of a patient until the first sensing site is positioned so that it is distal to the obstruction. The first catheter is used to monitor respiratory effort with generated signals indicative of respiratory effort. A second catheter having a second sensing site is positioned so that the second sensing site is near the nostrils. The second catheter is used to monitor actual respiration with generated signals indicative of actual respiration. The existence of the obstruction is verified by observing respiratory effort signals without corresponding actual respiration signals.

Abstract: A system and a method for evaluation of gastrointestinal function is presented. The system consists of a catheter, a recorder and software. The catheter includes one or more CdTe sensors for measuring isotope activity. The catheter CdTe sensors are placed in the gastrointestinal tract to measure gastric emptying or gastrointestinal output after administration of radiolabeled liquid or solid meals. Data is stored in the recorder or displayed online on a computer screen. Other parameters such as pH can be added for a more complete evaluation of gastrointestinal function. The computer software is written for the Windows environment. The software includes provisions for general ambulatory and stationary data acquisition. The software also includes realtime analysis combined with an extensive patient journal where all items are described as objects in understandable userfriendly language connected to a database.

Abstract: A perfusion catheter is designed to be used both as an exploring catheter for measuring potential difference across the gastrointestinal wall and for simultaneous measurement of pressure at the same site. The catheter includes a perfusion lumen into which an Ag/AgCl wire is inserted as an electrode thus avoiding the need of half cells and bridges. By perfusing saline around the wire, the environment is kept constant around the wire, a prerequisite for the electrode. The flow rate of the distal end of the lumen is altered by making the diameter of the outlet different to the diameter of the lumen. The perfused solution is also used to measure pressure.

Abstract: A system and a method for monitoring intragastrointestinal concentrations of ammonium, and urease, during short or prolonged periods is presented, as an indicator of the presence and activity of an intragastrointestinal Helicobacter Pylori ("HP") infection, and of other bacterial infections that are similarly located. Ambulatory monitoring is possible. This system and method may be used in the evaluation of treatments for HP and other bacterial infection in the patient. A method is also presented to increase the diagnostic accuracy of the system and method by ingesting urea immediately before or during the monitoring.

Abstract: An ambulatory system for recording and analyzing gastroesophageal reflux is presented. The system comprises a digital recorder, an analysis software package and a catheter for measurement of changes in esophageal impedance. For the first time, gastroesophageal reflux can be detected with a pH above 4 (called alkaline reflux), which is the normal pH environment of the healthy esophagus. In addition, one embodiment of the invention allows for the determination of the direction of flow of the detected material in the esophagus, thus enabling the system to distinguish between swallowed saliva and alkaline gastroesophageal reflux. In yet a further embodiment, the present invention allows for recording and analysis of reflux on a non-invasive basis, by using pairs of externally worn impedance sensors. In another embodiment, the invention measures impedance simultaneously with other bio-parameters, such as pH or pressure.